Polyrizon Ltd. (Nasdaq: PLRZ), a development stage biotech company specializing in innovative intranasal hydrogels, has announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs). The studies aim to address the $3.15 billion epilepsy market, focusing on acute repetitive seizures and status epilepticus. Utilizing Polyrizon's proprietary drug delivery platform, the intranasal administration of BZDs is designed to offer rapid, targeted, and patient-friendly seizure rescue therapy. Conducted in collaboration with Professor Fabio Sonvico of the University of Parma, the studies leverage Polyrizon's Trap and Target™ (T&T) platform to enhance the emergency treatment of seizures, providing a faster and more accessible solution for managing acute seizures outside of clinical settings. This initiative marks a significant milestone in improving treatment options for epilepsy patients worldwide.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。